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Psoriasis may be treated with ultraviolet B from
lamps that have a broad emission spectrum or, more
effectively, with lamps that have a narrow emission
spectrum at 311 6 2 nm. There are con¯icting
reports of either greater or lesser burning episodes
with narrow-band compared to broad-band ultra-
violet B, even when treatments are based on pre-
determined minimal erythema dose measurements.
This suggests that either the characteristics of the
dose±response curve for erythema or the time course
for erythema may be different for the two lamps.
We examined the erythemal response to narrow-
band and broad-band ultraviolet B in 12 patients
with psoriasis. A geometric series of 10 doses from
each lamp type were used on nonlesional skin on the
back. Dose±response curves were constructed from
re¯ectance measurements of erythema at 24 h and
72 h after irradiation. No signi®cant difference was
found in steepness of the erythema dose±response
curve for the two lamps at 24 or 72 h. Persistence of
erythema was assessed as the percentage of erythema
remaining at 72 h. The mean persistence was 63%
for narrow-band and 64% for broad-band lamps
(p = 0.94). Therefore, in terms of erythemal response,
no evidence has been found for a difference in burn-
ing potential for the two lamps. Key words: dose±
response curve/erythema/psorasis/UVB phototherapy. J
Invest Dermatol 117:1318±1321, 2001
U
ltraviolet B (UVB, 290±320 nm) phototherapy is an
established treatment for psoriasis. Traditionally,
¯uorescent sources emitting a wide range of UV
wavelengths (broad-band lamps) have been used,
e.g., Westinghouse FS-40, or Philips TL-12.
Following the observation that wavelengths of 290 nm or less
(which are present in broad-band sources) do not contribute to
clearance of psoriasis (Parrish and Jaenicke, 1981), a new lamp was
developed in which 85% of the UVB emission is at 311 6 2 nm
(TL-01, Philips), a spectral region known to be effective at clearing
psoriasis (Fischer, 1976; Parrish and Jaenicke, 1981). These
``narrow-band'' lamps have been shown to be signi®cantly more
effective in the treatment of psoriasis than broad-band lamps (van
Weelden et al, 1988; Storbeck et al, 1993; Coven et al, 1997),
although the magnitude of the difference in response appears to be
small. Narrow-band UVB lamps are now increasingly used for
treatment of psoriasis (British Photodermatology Group, 1997;
Stern, 1997), although concerns remain about their long-term
safety (Flindt-Hansen et al, 1991; Gibbs et al, 1995).
When treating psoriasis with UVB, the dose of radiation that can
be given is limited by the potential for developing erythema or
burning on nonlesional skin (Speight and Farr, 1994). It is routine
clinical practice to measure each patient's minimal erythema dose
(MED) before commencing phototherapy, and then to give around
0.7 MED for the ®rst exposure. Even when treatments are based
upon predetermined MED measurements there are con¯icting
reports of either greater (Hansen et al, 1994; Alora and Taylor,
1997) or lesser (Green et al, 1988, 1992; Picot et al, 1992) burning
episodes with narrow-band compared with broad-band UVB. It
has also been suggested that narrow-band induced erythema is
more intense and long lasting (Coven et al, 1997).
If a genuine difference in burning exists for the two lamp types
then it might be expected that either (i) the characteristics of the
dose±response curves for UV erythema would be different (a
steeper curve for a particular lamp would increase the risk of
burning as a small increase in dose would cause a large increase in
erythema), or (ii) erythema persistence may be different (erythema
lasting longer would increase the potential for burning).
It is known that the dose±response curve for erythema induced
by UVC radiation (250±290 nm) is shallower than that for UVB
wavelengths (Farr and Diffey, 1985). On this basis it might be
predicted that broad-band lamps, which have signi®cant emission
within the UVC waveband, would induce a shallower erythemal
response than narrow-band lamps, which have negligible UVC
emission. For example, the UVC component from the broad-band
lamp used in this study (Philips TL-12) is 9.2% of the total
unweighted UV irradiance (250±400 nm), which represents 28.1%
of the erythemally effective irradiance.
One previous study (Hansen et al, 1994) has shown a steeper
24 h dose±response curve for narrow-band compared with broad-
band erythema. Another (Leenutaphong and Sudtim, 1998),
however, found no difference. The time course of erythema
from these two lamps has not been compared. The purpose of our
study was to compare the erythema induced by broad-band and
narrow-band UVB lamps, looking particularly at the dose±response
and time course.
MATERIALS AND METHODS
Patients We studied 12 adult patients with psoriasis (nine female;
median age 41 y; range 21±57) who were about to commence a course
of narrow-band UVB phototherapy. None of the patients had a history
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of abnormal sunlight sensitivity, and none was receiving potentially
photosensitizing medication. No patient had received UV phototherapy
or signi®cant sun exposure to the skin of the back for a period of 4 mo
prior to the study. They were of skin types I (n = 2), II (n = 8), and IV
(n = 2).
Photoirradiation apparatus The irradiation sources (Fig 1) were a
narrow-band UVB ¯uorescent lamp (TL-20 W/01; Philips, The
Netherlands) and a broad-band UVB ¯uorescent lamp (TL-20 W/12;
Philips), each housed in a fully enclosed luminaire. Ten closely spaced
apertures, each 8 3 12 mm, were milled into the lamp diffuser. One
aperture was open; the rest were backed with metal foil attenuators, each
perforated with a grid of holes of differing sizes (Fig 2). This allowed
subjects to be exposed simultaneously to a geometric series of 10 UV
doses, with a dose range of approximately 7:1. The principle of the
attenuator design and its use for phototesting has been described in detail
previously (Diffey et al, 1993; Gordon et al, 1998). Irradiance was
measured using a radiometer (type IL1400a; International Light) and
UVB detector that had been calibrated spectroradiometrically (Diffey,
1995). The unweighted open aperture UV (250±400 nm) irradiance at
the skin surface was 2.86 mW per cm2 (TL-01) and 3.41 mW per cm2
(TL-12). The UVB 290±320 nm component of the total UV (250±
400 nm) irradiance was 80% for the TL-01 lamp and 62% for the TL-12
lamp. Doses given in this paper are expressed as unweighted total UV
doses.
Phototesting protocol The patients were phototested on clinically
normal skin of the mid-back. For patients of skin types I to III, a dose
range of 35±238 mJ per cm2 was used for broad-band (TL-12)
irradiation and 180±1360 mJ per cm2 for narrow-band (TL-01)
irradiation. These dose ranges were chosen with the aim of achieving an
approximately equal range of erythemal responses with the two lamps,
and were based on the erythema action spectrum of human skin
(McKinlay and Diffey, 1987). The doses from both of the lamps were
increased by 10% for patients of skin type IV.
Measurement of erythema The MED, de®ned as the smallest dose
of radiation to result in just detectable erythema, was assessed visually at
24 and 72 h after irradiation. Objective measurements of erythema were
made using a commercially available re¯ectance instrument (Diastron,
Figure 1. The spectral power distribution for the two lamps. Solid
line, TL-01; dashed line, TL-12.
Figure 2. The phototesting template. The metal foil attenuators
allow simultaneous delivery of 10 different UVB doses.
Figure 3. An example of the dose±response curve in one patient
for broad-band (TL-12) and narrow-band (TL-01) induced
erythema at 24 h after irradiation. Each data point represents the
mean (6 SEM) increase in erythema index compared with nonirradiated
sites. The solid line is the sigmoid dose±response curve computer-®tted to
the data points. The sigmoid curve has been used to calculate D0.025 (the
dose required to cause an increase in erythema index of 0.025 units,
equivalent to just perceptible erythema) and D0.1 (the dose required to
cause an increase of erythema index of 0.1 units, equivalent to moderate
or symptomatic erythema).
Figure 4. The D0.1:D0.025 ratio was not signi®cantly different for
narrow-band (TL-01) and broad-band (TL-12) lamps. Data points
represent results on individual patients. The mean ratios (arrows) at 24 h
were 1.73 (95% con®dence interval 1.36±2.10) for TL-01 and 1.83
(1.52±2.14) for TL-12; p = 0.64, paired t test. At 72 h the mean ratios
were 1.63 (1.34±1.95) for TL-01 and 1.80 (1.51±1.94) for TL-12;
p = 0.47.
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Hampshire, U.K.) (Diffey et al, 1984). Erythema measurements were
made in triplicate at each irradiated site, and at adjacent nonirradiated
skin. In each patient, for each of the two UVB sources and at both times
of measurement, the increase in mean erythema index compared with
nonirradiated skin was plotted against the logarithm of the UV radiation
dose. Sigmoidal dose±response curves were ®tted using a graphics
computer program (GraphPad Prism 2.01, GraphPad Software, San
Diego, CA). These curves were then used to calculate the dose of
radiation required to cause an increase in erythema index of 0.025 units
(D0.025, equivalent to just perceptible erythema) and 0.1 units (D0.1,
equivalent to erythema of ``moderate'' intensity).
RESULTS
Out of the 12 patients studied, in nine cases complete data sets were
obtained suf®cient to construct four dose±response curves for each
patient (both lamps at both times of measurement). In the
remaining three patients, the range of erythema values was
insuf®cient to calculate the D0.025 and D0.1 values for one or
more of their curves. The data points were well-®tted by the
sigmoid dose±response curves (R2 values ranged from 0.95 to 0.99).
The median MED for broad-band (TL-12) UVB was 67.9 mJ per
cm2 (range 38.1±130.7) at 24 h and 85.8 mJ per cm2 (67.9±130.7)
at 72 h. The median MED for narrow-band (TL-01) UVB was 360
mJ per cm2 (range 290±560) at 24 h and 470 mJ per cm2 (range
350±860) at 72 h.
Steepness of dose±response The ratio D0.1:D0.025 calculated
from each patient's dose±response curve (Fig 3) was used as a
measure of curve steepness. This value represents the UV dose
increment ratio that would be required to move from just
perceptible to moderate or symptomatic erythema. There was no
signi®cant difference between the mean D0.1:D0.025 ratio for broad-
band and narrow-band UVB at 24 h or 72 h after irradiation
(Fig 4).
Persistence of erythema As an indication of persistence of
erythema from 24 h to 72 h after irradiation, the D0.1 calculated
from the 24 h erythema measurements was inserted into the
corresponding 72 h curve, and the intensity of erythema that
would have remained by 72 h was calculated (Fig 5). There was no
signi®cant difference in the mean persistence of erythema for
broad-band compared with narrow-band lamps (Fig 6).
DISCUSSION
We did not ®nd a signi®cant difference in the steepness of the
dose±response curves for erythema induced by broad-band and
narrow-band UVB lamps, nor in the degree of resolution of
erythema from 24 to 72 h. Our results do not therefore support the
clinical impression of a difference in burning potential or erythema
persistence for the two lamp types.
As expected, the MED for broad-band UVB was considerably
lower than that for narrow-band UVB. This difference [which can
be predicted from the emission spectrum of the lamps and the
erythema action spectrum of human skin (McKinlay and Diffey,
1987)], does not imply a difference in burning potential for the two
lamps, provided, of course, that exposure times are based on a
patient's predetermined MED. Although the MED is a widely used
and useful measure of an individual's erythemal sensitivity, it is a
threshold response and gives no information concerning response
of the skin to higher doses of radiation, potentially an important
factor in burning potential. We therefore used an objective method
to quantify erythema, allowing the construction of dose±response
curves for individual patients. As a measure of curve steepness, we
calculated the ratio D0.1:D0.025, in other words the dose increment
factor that would cause an increase in erythema from just
perceptible erythema (D0.025) to ``moderate'' erythema (D0.1) likely
to be symptomatic if involving a large area of skin. We used this
ratio as a measure of curve steepness rather than the maximum slope
of the ®tted sigmoid dose±response curve, as the latter parameter is
quite dependent on analysis of a complete dose±response curve. In
several of the patients that we studied, the plateau part of the dose±
response curve, where maximum erythema is reached, was not
achieved. In addition, the ratio D0.1:D0.025 refers to a clinically
important region of the response, just above the MED, and gives an
easily understandable measure of the likely effect of a given dose
increment. The similar values of D0.1:D0.025 that we found for the
two UVB sources (around 1.8) may be compared with a typical
response for psoralen plus UVA erythema of around 3.5 (Ibbotson
and Farr, 1999; P.M. Farr, unpublished data), where the higher
ratio indicates a much shallower dose±response curve.
We used the individual patients' dose±response curves to
calculate the persistence of erythema from 24 to 72 h after
irradiation. No signi®cant difference in mean percentage persist-
ence was found for the two lamps, although, interestingly, for both
sources there was considerable interpatient variability (Fig 6).
Previous studies comparing erythema from broad-band and
narrow-band UVB lamps have shown con¯icting results (Hansen
Figure 5. Calculation of persistence of erythema. Dose±response
curves for broad-band UVB erythema are shown for one patient. The
D0.1 calculated from the 24 h curve (d) was inserted into the
corresponding 72 h curve (s) and the intensity of erythema that would
have remained by 72 h was calculated. In this patient 0.051 units of
erythema remained (i.e., 51% of the 24 h intensity).
Figure 6. Persistence of erythema from 24 h to 72 h was not
signi®cantly different for narrow-band (TL-01) and broad-band
(TL-12) lamps. Data points represent results on individual patients.
Persistence of erythema at 72 h is expressed as a percentage of the
erythemal intensity at 24 h. The mean persistence (arrows) was 63% (95%
con®dence interval 43±84) for TL-01 and 64 (45±80) for TL-12; p
= 0.94, paired t test.
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et al, 1994; Leenutaphong and Sudtim, 1998). Our results are in
keeping with those of Leenutaphong and Sudtim (1998), ®nding
no difference in steepness of the dose±response for broad-band and
narrow-band lamps at 24 h after irradiation. In clinical practice, the
time to resolution of erythema may be an important factor with
regard to burning. Previous investigators limited their comparison
to a single time-point of 24 h. We have now shown that there is no
difference in slope or resolution of erythema up to 72 h after
irradiation.
We have found no evidence, at least in terms of erythema
production, to support the clinical impression (Green et al, 1988;
1992; Picot et al, 1992; Hansen et al, 1994; Alora et al, 1997) of a
difference in burning potential between broad-band and narrow-
band lamps. Neither is there evidence of longer-lasting erythema
with narrow-band lamps as suggested by Coven et al (1997). We
have not examined the change in erythemal sensitivity during a
course of UVB phototherapy; a difference in the rate or degree of
photoadaptation might account for a difference in burning potential
for narrow-band and broad-band lamps.
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